Blog
31 Articles
Research Highlights from ASCO GI 2026
The latest research on drugs targeting KRAS and new immuotherapy combinations were among the highlights of ASCO GI 2026.
PLATINUM Clinical Trial Actively Recruiting
The PLATINUM clinical trial, for patients with BRCA and PALB2 mutations, seeks participants. Dr. Andrew Ko outlines the trial.
Gathering Information for the Right Treatment
Staci and Rich Grodin applied their medical information research skills when Rich was diagnosed with pancreatic cancer.
Extensive Family History and Genetic Testing Leads to Early Detection
Sidney Levinson and his doctor were aware of his BRCA1/2 mutations so when an MRI was recommended for screening, Sidney did it.
Sometimes Things Get Worse Before They Get Better
Matthew Rosenblum thought his time was limited after a pancreatic cancer diagnosis at age 32, but he’s a BRCA2 carrier, which opened treatment options.
A Long Journey That Began With Pancreatitis
Paul Suntup’s diagnosis of acinar cell pancreatic cancer was just the start of a long treatment journey, but he’s still here.
Targeted Therapy for Cancers Carrying the PALB2 Mutation
Researchers are testing a type of targeted therapy called a PARP inhibitor for cancers carrying the PALB2 mutation.
Taking Chances to Beat Pancreatic Cancer
With a family history of pancreatic cancer, Jay Bozick discovered he carries the BRCA2 mutation, which directed his treatment.
Cherishing the Simple Things
Elizabeth O’Connor has a PALB2 genetic mutation so her stage IV pancreatic cancer has responded to immunotherapy.
New Study Aims to Reduce Recurrence Risk for Select Patients
Dr. Kim A. Reiss is leading a study of the PARP inhibitor olaparib to delay or prevent a recurrence of surgically removed pancreatic cancer.
The Butterfly Effect and Living Every Day to My Fullest
Because Helene Avraham-Katz has the BRCA2 mutation, certain chemotherapies work better and she is eligible for specific clinical trials.
Testing a PARP Inhibitor for Metastatic Pancreatic Cancer Patients with DNA Repair Mutations
Researchers are testing a PARP inhibitor that is effective for cancers in pancreatic cancer patients with DNA repair mutations.
BRCA Mutation Determines My Pancreatic Cancer Treatment
Chris Treubert started with one type of chemotherapy but when the results of genetic testing showed a BRCA mutation he changed treatment.
A Second Opinion Makes the Difference
Irma Infante refused to give up after a stage IV pancreatic cancer diagnosis. She went for a second opinion and better treatment options.
Genetic Testing Leads Me to a PARP Inhibitor Trial
Harvey Parker had genetic testing as part of his initial pancreatic cancer treatment. The BRCA2 mutation led him to a PARP inhibitor clinical trial.